With the wrong architecture in place, AI algorithms can nudge biopharmaceutical developers toward unpredicted and misaligned ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

In the rapidly evolving world of life sciences, companies are constantly seeking ways to optimize their business structures to better navigate the complex landscape of drug development and financing.

Biopharma companies face a long journey with each drug they research, test, and — if all goes right — bring to market. And just as new drug development moves forward in phases, so too should your ...

Spinning off a $4 billion biopharma business is no easy task. Integrated functions need to be separated, governance boards created, leadership teams assembled, and corporate headquarters established.

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

As pharmaceutical manufacturers grow, they often pursue external sources of innovation to supplement their own R&D efforts. A recent study found that 45% of drugs in the pipelines of 20 large ...

Biotech is the most honest leadership environment in the world. Science does not soften bad news. Markets do not wait for leaders to feel ready. And the pressure does not lift between a failed trial, ...

Vivani’s subdermal implant NanoPortal device, a platform drug delivery technology, is designed to deliver a near-constant and minimally fluctuating dose of an active pharmaceutical drug for a duration ...

Continuous improvement doesn’t just depend upon Lean principles and/or zero-based budgeting. It depends upon people inspired by a culture that values learning, promotes problem-solving skills, and ...

As the fentanyl epidemic rages on, opioid antagonist rescue agents like Narcan, Kloxxado, and Opvee have become omnipresent. Like defibrillators and EpiPens, advocates insist they should be available ...

I’ve spent most of my career in life sciences, and like many in the field, I’ve seen how slow and cautious the industry can be when embracing new technology. It’s understandable. We work in a highly ...